Literature DB >> 7305319

Acyclovir treatment of experimental simian varicella infection of monkeys.

K F Soike, A D Felsenfeld, P J Gerone.   

Abstract

Replication of simian varicella virus (SVV) in Vero cell cultures was inhibited by acyclovir, 9-(2-hydroxyethoxymethyl)guanine (ACV), at a concentration of 10 micrograms/ml in culture medium. Intravenous administration of ACV at 10 mg/kg twice a day for 10 days or 15 mg/kg three times a day for 5 days to patas monkeys (Erythrocebus patas) beginning 48 h after SVV inoculation blocked the appearance of rash and other clinical symptoms but did not affect viremia. ACV treatment of African green monkeys (Cercopithecus aethiops) at 10 mg/kg twice a day by intravenous injection beginning 24 or 72 h after SVV inoculation and continuing for 10 days had no effect on clinical symptoms, including the development of rash, or on the appearance of viremia. The minimal therapeutic results could be due to the observation that doses of 10 or 15 mg/kg produced plasma levels of ACV which were lower than 5 micrograms/ml, the concentration that inhibited SVV multiplication in vitro, and decayed rapidly.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7305319      PMCID: PMC181690          DOI: 10.1128/AAC.20.3.291

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Effect of 9-(2-hydroxyethoxymethyl)guanine on herpesvirus-induced keratitis and iritis in rabbits.

Authors:  H E Kaufman; E D Varnell; Y M Centifanto; S D Rheinstrom
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

2.  Phosphonoacetic acid in the treatment of simian varicella.

Authors:  A D Felsenfeld; C R Abee; P J Gerone; K F Soike; S R Williams
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  In vitro susceptibility of varicella-zoster virus to acyclovir.

Authors:  K K Biron; G B Elion
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

4.  Acyclovir kinetics after intravenous infusion.

Authors:  P de Miranda; R J Whitley; M R Blum; R E Keeney; N Barton; D M Cocchetto; S Good; G P Hemstreet; L E Kirk; D A Page; G B Elion
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

5.  Induction of thymidine kinase and DNase in varicella-zoster virus-infected cells and kinetic properties of the virus-induced thymidine kinase.

Authors:  Y C Cheng; T Y Tsou; T Hackstadt; L P Mallavia
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

6.  A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine].

Authors:  R P Quinn; P de Miranda; L Gerald; S S Good
Journal:  Anal Biochem       Date:  1979-10-01       Impact factor: 3.365

7.  Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers.

Authors:  B R Jones; D J Coster; P N Fison; G M Thompson; L M Cobo; M G Falcon
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321

8.  Enzymatic basis for the selective inhibition of varicella-zoster virus by 5-halogenated analogues of deoxycytidine.

Authors:  M J Dobersen; M Jerkofsky; S Greer
Journal:  J Virol       Date:  1976-11       Impact factor: 5.103

9.  Therapy of experimental herpes simplex encephalitis with aciclovir in mice.

Authors:  N H Park; D Pavan-Langston; S L McLean; D M Albert
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

10.  Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice.

Authors:  H J Field; S E Bell; G B Elion; A A Nash; P Wildy
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

View more
  10 in total

Review 1.  Screening for new agents.

Authors:  B Oberg; L Vrang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

Review 2.  Simian varicella in old world monkeys.

Authors:  Wayne L Gray
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

3.  Identification and analysis of the simian varicella virus thymidine kinase gene.

Authors:  C Y Pumphrey; W L Gray
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

4.  Simian varicella virus DNA in dorsal root ganglia.

Authors:  R Mahalingam; D Smith; M Wellish; W Wolf; A N Dueland; R Cohrs; K Soike; D Gilden
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

Review 5.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

6.  Oral BVDU treatment of varicella and zoster in children with cancer.

Authors:  Y Benoit; G Laureys; M J Delbeke; E De Clercq
Journal:  Eur J Pediatr       Date:  1985-01       Impact factor: 3.183

Review 7.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

8.  Activity of 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil against simian varicella virus infections in African green monkeys.

Authors:  K F Soike; C Cantrell; P J Gerone
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

9.  CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection.

Authors:  Kristen Haberthur; Flora Engelmann; Byng Park; Alex Barron; Alfred Legasse; Jesse Dewane; Miranda Fischer; Amelia Kerns; Monica Brown; Ilhem Messaoudi
Journal:  PLoS Pathog       Date:  2011-11-10       Impact factor: 6.823

Review 10.  Animal models of varicella zoster virus infection.

Authors:  Kristen Haberthur; Ilhem Messaoudi
Journal:  Pathogens       Date:  2013-05-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.